Rezolute Inc (RZLT) - Total Liabilities
Based on the latest financial reports, Rezolute Inc (RZLT) has total liabilities worth $11.50 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RZLT cash flow conversion to assess how effectively this company generates cash.
Rezolute Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Rezolute Inc's total liabilities have evolved over time, based on quarterly financial data. Check Rezolute Inc (RZLT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Rezolute Inc Competitors by Total Liabilities
The table below lists competitors of Rezolute Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Reform Culture Holdings Co Ltd
SHG:600636
|
China | CN¥118.95 Million |
|
STEP Energy Services Ltd
TO:STEP
|
Canada | CA$197.86 Million |
|
Jiangsu Jingyuan Environmental Protection Co Ltd
SHG:688096
|
China | CN¥1.00 Billion |
|
Tudor Gold Corp
V:TUD
|
Canada | CA$17.37 Million |
|
Asiacement
KO:183190
|
Korea | ₩1.08 Trillion |
|
Siddhi Acquisition Corp Class A Common stock
NASDAQ:SDHI
|
USA | $16.66 Million |
|
Izertis Sa
MC:IZER
|
Spain | €178.27 Million |
|
Polaris Media
OL:POL
|
Norway | Nkr1.93 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Rezolute Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RZLT market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rezolute Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rezolute Inc (2012–2025)
The table below shows the annual total liabilities of Rezolute Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.36 Million | +13.88% |
| 2024-06-30 | $11.73 Million | +55.44% |
| 2023-06-30 | $7.55 Million | +155.99% |
| 2022-06-30 | $2.95 Million | -82.14% |
| 2021-06-30 | $16.51 Million | +358.61% |
| 2020-06-30 | $3.60 Million | -65.71% |
| 2019-06-30 | $10.50 Million | +62.45% |
| 2018-06-30 | $6.46 Million | +207.65% |
| 2017-06-30 | $2.10 Million | -1.39% |
| 2016-06-30 | $2.13 Million | -3.57% |
| 2015-06-30 | $2.21 Million | +121.40% |
| 2014-06-30 | $997.92K | -81.05% |
| 2013-06-30 | $5.27 Million | +49835.36% |
| 2012-06-30 | $10.55K | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more